ABBOTT LABORATORIES — Director's Dealing 2019

Jun 6, 2019

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: ABBOTT LABORATORIES (ABT)
CIK: 0000001800
Period of Report: 2019-06-03

Reporting Person: Ginascol John F (Executive Vice President)

Holdings (Non-Derivative)

Security	Shares	Ownership
Common shares without par value	48617	Direct

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Option (right to buy)	$47.00	2025-02-19	Common shares (57721)		Direct
Option (right to buy)	$38.40	2026-02-18	Common shares (83333)		Direct
Option (right to buy)	$44.40	2027-02-16	Common shares (39953)		Direct
Option (right to buy)	$59.94	2028-02-15	Common shares (38669)		Direct
Option (right to buy)	$75.90	2029-02-21	Common shares (38190)		Direct

Footnotes

F1: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable in annual increments of 19,241 on February 20, 2016, 19,240 on February 20, 2017, and 19,240 on February 20, 2018.

F2: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable in annual increments of 27,778 on February 19, 2017, 27,777 on February 19, 2018, and 27,778 on February 19, 2019.

F3: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable in annual increments of 13,318 and 13,317 on February 17, 2018 and February 17, 2019, respectively, and an increment of 13,318 becomes exercisable on February 17, 2020.

F4: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. The option became exercisable in an annual increment of 12,890 on February 16, 2019, and annual increments of 12,889 and 12,890 become exercisable on February 16, 2020 and February 16, 2021, respectively.

F5: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 12,730 on February 22, 2020, 12,730 on February 22, 2021, and 12,730 on February 22, 2022.